Blog Tag
4 articles tagged with Oncology. The newest post is from May 6, 2026.
ASCO 2026 should bring a dense run of lung cancer updates, and a handful of studies stand out because they could shape frontline treatment decisions, refine biomarker-specific standards, or push targeted therapy further into earlier-stage disease. Some of these are classic stock-moving readouts tied to a single asset. Others matter more because they can shift the field's treatment logic even if the immediate market reaction is smaller.
The American Association for Cancer Research Annual Meeting remains one of the most important catalyst windows in biotechnology, and AACR 2026 is already proving why investors watch it so closely. As of April 20, the conference has delivered a steady stream of data and clinical updates, with more still expected throughout the week.
Combination therapy means using two or more treatments together to treat a disease. In biotech, the term matters because many diseases are too complex to respond well to a single therapy alone. Combining drugs can improve efficacy, reduce resistance, or create a more durable clinical benefit.
Line of therapy refers to where a treatment fits in the sequence of care for a disease. A therapy may be used first-line, second-line, third-line, or later-line depending on what is typically given before it. In biotech, line of therapy matters because it helps define how broadly a drug can be used and how much commercial opportunity it may have.
